|
Name |
Synerazol
|
| Molecular Formula | C22H23NO7 | |
| IUPAC Name* |
(5S,8S,9R)-8-benzoyl-2-[(2S,3R)-3-[(Z)-but-1-enyl]oxiran-2-yl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
|
|
| SMILES |
CC/C=C\[C@@H]1[C@H](O1)C2=C(C(=O)[C@@]3(O2)[C@H]([C@@](NC3=O)(C(=O)C4=CC=CC=C4)OC)O)C
|
|
| InChI |
InChI=1S/C22H23NO7/c1-4-5-11-14-16(29-14)15-12(2)17(24)21(30-15)19(26)22(28-3,23-20(21)27)18(25)13-9-7-6-8-10-13/h5-11,14,16,19,26H,4H2,1-3H3,(H,23,27)/b11-5-/t14-,16+,19-,21-,22-/m1/s1
|
|
| InChIKey |
UCUHTBUWKCQZNJ-WZNGDJORSA-N
|
|
| Synonyms |
Synerazol; CHEMBL473144; (5S,8S,9R)-8-benzoyl-2-[(2S,3R)-3-[(Z)-but-1-enyl]oxiran-2-yl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
|
|
| CAS | NA | |
| PubChem CID | 11165858 | |
| ChEMBL ID | CHEMBL473144 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 413.4 | ALogp: | 1.5 |
| HBD: | 2 | HBA: | 7 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 115.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 30 | QED Weighted: | 0.314 |
| Caco-2 Permeability: | -5.294 | MDCK Permeability: | 0.00001870 |
| Pgp-inhibitor: | 0.915 | Pgp-substrate: | 0.947 |
| Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.024 |
| 30% Bioavailability (F30%): | 0.399 |
| Blood-Brain-Barrier Penetration (BBB): | 0.84 | Plasma Protein Binding (PPB): | 81.79% |
| Volume Distribution (VD): | 1.859 | Fu: | 16.58% |
| CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.395 |
| CYP2C19-inhibitor: | 0.032 | CYP2C19-substrate: | 0.658 |
| CYP2C9-inhibitor: | 0.028 | CYP2C9-substrate: | 0.025 |
| CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.07 |
| CYP3A4-inhibitor: | 0.076 | CYP3A4-substrate: | 0.779 |
| Clearance (CL): | 6.225 | Half-life (T1/2): | 0.325 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.871 |
| Drug-inuced Liver Injury (DILI): | 0.976 | AMES Toxicity: | 0.522 |
| Rat Oral Acute Toxicity: | 0.385 | Maximum Recommended Daily Dose: | 0.123 |
| Skin Sensitization: | 0.315 | Carcinogencity: | 0.261 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
| Respiratory Toxicity: | 0.845 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003742 | ![]() |
0.670 | D08UMH | ![]() |
0.282 | ||
| ENC002724 | ![]() |
0.670 | D0Y7RW | ![]() |
0.275 | ||
| ENC003765 | ![]() |
0.670 | D07RGW | ![]() |
0.270 | ||
| ENC002999 | ![]() |
0.612 | D0MB8I | ![]() |
0.270 | ||
| ENC003736 | ![]() |
0.482 | D0W7RJ | ![]() |
0.268 | ||
| ENC002521 | ![]() |
0.305 | D0WV4M | ![]() |
0.262 | ||
| ENC001726 | ![]() |
0.299 | D0E3WQ | ![]() |
0.259 | ||
| ENC003270 | ![]() |
0.290 | D0D4YZ | ![]() |
0.257 | ||
| ENC005174 | ![]() |
0.290 | D06CWH | ![]() |
0.255 | ||
| ENC003619 | ![]() |
0.290 | D0Z9NZ | ![]() |
0.255 | ||